Pharma & life sciences
Specialist experience and industry expertise to help you navigate disruption, embrace innovation and grow with confidence.
Anti-bribery and corruption in the sector
IndustriesHealthcare & Life SciencePharma & life sciencesPharma & life sciences insights
Anti-bribery and corruption in the sector
Nigel Layton, our Global Head of Pharma & Life Sciences and UK Head of Investigations, gives his insight on anti-bribery and corruption within the pharma and life sciences sector.
Since 2011 the pharma and life sciences industry has seen 23 prosecutions in the US and the UK and $1.75 billion worth of fines. Speaking to Tarifa Simpson, our Healthcare & Life Sciences Co-Lead, Nigel discusses the tightening regulatory environment, third-party due diligence and the importance of robust, up to date compliance and whistleblowing programs.
Related pages
Mazars sponsors FT Live Global Pharma Summit
Mazars is committed to supporting the pharma and life sciences sector; helping companies to navigate disruption, embrace innovation and grow with confidence. That’s why we recently partnered with FT Live for their Global Pharma and Biotech Summit - bringing the industry together to explore the latest trends, share top expertise and drive growth.
Pharma & life sciences insights
Explore all our expert analysis and insights for the pharma and life sciences sector.
National contacts
Nigel Layton Partner - Head of Pharma & Life Sciences London
